Novavax, Inc.
NVAX
$7.95
-$0.43-5.13%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 682.16M | 885.19M | 987.67M | 996.61M | 983.71M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 682.16M | 885.19M | 987.67M | 996.61M | 983.71M |
| Cost of Revenue | 569.64M | 728.52M | 786.30M | 905.96M | 1.04B |
| Gross Profit | 112.52M | 156.67M | 201.37M | 90.65M | -53.15M |
| SG&A Expenses | 323.59M | 405.48M | 445.99M | 427.21M | 457.45M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 914.09M | 1.18B | 1.27B | 1.37B | 1.54B |
| Operating Income | -231.93M | -290.02M | -285.83M | -377.77M | -551.81M |
| Income Before Tax | -176.62M | -279.74M | -288.88M | -395.60M | -543.03M |
| Income Tax Expenses | 10.88M | 5.12M | 5.46M | 3.11M | 2.03M |
| Earnings from Continuing Operations | -187.50 | -284.86 | -294.33 | -398.71 | -545.06 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -187.50M | -284.86M | -294.33M | -398.71M | -545.06M |
| EBIT | -231.93M | -290.02M | -285.83M | -377.77M | -551.81M |
| EBITDA | -183.44M | -243.25M | -240.44M | -333.45M | -510.59M |
| EPS Basic | -1.22 | -2.16 | -2.67 | -3.11 | -5.47 |
| Normalized Basic EPS | -0.85 | -1.28 | -1.61 | -1.80 | -3.30 |
| EPS Diluted | -1.32 | -2.26 | -2.77 | -3.18 | -5.54 |
| Normalized Diluted EPS | -0.93 | -1.35 | -1.68 | -1.87 | -3.38 |
| Average Basic Shares Outstanding | 608.59M | 572.02M | 515.40M | 456.39M | 402.63M |
| Average Diluted Shares Outstanding | 626.06M | 589.50M | 532.88M | 471.09M | 417.33M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
